Europe's Choice
Geopolitical shifts are reshaping life sciences. Europe can build on its strengths and lead or stand still and fall behind. What will it choose?
LEARN MOREHow can we ensure Europeans don't miss out on the latest advances in treatment?
EFPIA is asking EU leaders to work together with industry to create opportunities to, once again, make the region a world-leader in life sciences
EFPIA Code of Practice and relationships with patient organisations and healthcare professionals.
Latest Updates
VIEW ALL-
Statements & press releases 26.03.26
PFAS restrictions: risks for patients and companies operating in Europe
EFPIA reaction to the publication of ECHA scientific committees’ opinions on PFAS Restriction.
Read Article -
Blog articles 24.03.26
World TB Day 2026: Working together to end tuberculosis (Guest blog)
Tuberculosis (TB) remains the world’s deadliest infectious diseases. Not only do more than 10 million people fall ill with it every year, increasing drug...
Read Article -
Statements & press releases 17.03.26
Turning EU excellence in science into commercial success could add more than €120billion to EU economy...
New research provides the first comprehensive overview of the EU’s attractiveness as a destination for pharmaceutical investment.
Read Article -
EFPIA Event 21.04.26
Europe’s Choice: Investing in sustainable health systems
At a time when health budgets are strained, public finances are under pressure, the health workforce crisis is deepening, and Europe faces unprecedented...
View Event -
External Event 19.05.26
European Pharmaceutical Law Forum
The European pharmaceutical market is facing a moment of profound change. With sweeping updates to the EU pharmaceutical package, a growing maze of regulatory...
View Event -
External Event 03.06.26
European Conference on Rare Diseases and Orphan Products (ECRD) 2026
The next ECRD will be held on 3 & 4 June 2026 in Prague and will be titled “Rare Diseases in a Changing & Competitive Europe: Shaping policies to address...
View Event